Metabolic and cardiovascular effects of very‐low‐calorie diet therapy in obese patients with Type 2 diabetes in secondary failure: outcomes after 1 year

Abstract

The absence of a control group is a major limitation, but the results indicate that 8 weeks of VLCD treatment may be effective and well tolerated in symptomatic obese patients with T2DM in secondary failure, producing sustained cardiovascular and metabolic improvements after 1 year. VLCD therapy is a treatment option that deserves greater consideration in this difficult-to-treat patient population.